Compound · clinical trials

Camrelizumab clinical trials

Also listed in trial records as SHR-1210, B2: TROP2 ADC with Camrelizumab

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 108 trials in our China register that name Camrelizumab as an intervention. Synced 8 Nov 2026

108Current trials

72Recruiting now

53Lead sponsors

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 8 Nov 2026 · Editorial standards

At a glance

Camrelizumab is named as an intervention in 108 current clinical trials in our China register. 72 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (16). The most-studied condition is Nasopharyngeal Carcinoma.

Where Camrelizumab is approved

All regulators →

USUnited States (FDA)

No FDA approval of a single-substance product in Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

No new-drug Notice of Compliance since 1994

First new-drug NOC

1 EU orphan designation, most recently for treatment of hepatocellular carcinoma (25 Jul 2024, positive)

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

How Camrelizumab works

All drug targets →

Programmed cell death protein 1 antagonist Antagonist
Target: PDCD1 programmed cell death 1
ChEMBL only

Other medicines acting on PDCD1

Pembrolizumab Nivolumab Tislelizumab Sintilimab Toripalimab Cadonilimab Serplulimab Cemiplimab Dostarlimab Pucotenlimab Zimberelimab Penpulimab +8 more

Diseases it has been tested for in clinical trials, by furthest phase

Breast cancerPhase 3
Cervical cancerPhase 3
Classic Hodgkin lymphomaPhase 3
Esophageal cancerPhase 3
Esophageal squamous cell carcinomaPhase 3
Gastric adenocarcinomaPhase 3
Gastric cancerPhase 3
Gastroesophageal junction adenocarcinomaPhase 3
Head and neck squamous cell carcinomaPhase 3
Hepatocellular carcinomaPhase 3

92 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297715, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9758, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Camrelizumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting7267%
Not yet open1716%
Active, closed1817%
By invitation11%

Trials by phase

Phase 26661%
Phase 31817%
Phase 2/366%
Phase 1/266%
Observational55%
Phase 422%
Phase 122%
Not applicable22%
Early Phase 111%

Clinical trials of Camrelizumab

108 trials

Study	Phase	Status	Lead sponsor	Registers
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) NCT07744698 · ClinicalTrials.gov ↗ · Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 4	Recruiting	Anhui Provincial Cancer Hospital	China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC NCT04342910 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma NCT04453826 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer, Chemotherapy, Radiotherapy	Phase 3	Recruiting	Sun Yat-sen University	China
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma NCT04944914 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma NCT05613478 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Preoperative	Phase 3	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. NCT05760378 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 3	Recruiting	Fudan University	China
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy NCT05772208 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Fudan University	China
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma NCT05789043 · ClinicalTrials.gov ↗ · Acral Melanoma	Phase 3	Recruiting	Peking University Cancer Hospital & Institute	China
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) NCT05999149 · ClinicalTrials.gov ↗ · TNBC - Triple-Negative Breast Cancer	Phase 3	Recruiting	Fudan University	China
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer NCT06086457 · ClinicalTrials.gov ↗ · Esophageal Neoplasms	Phase 3	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial NCT06438627 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	XIANG YANQUN	China
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer NCT06889688 · ClinicalTrials.gov ↗ · Breast Cancer Stage IV, Triple -Negative Breast Cancer	Phase 3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC NCT04803539 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2/3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC NCT06288373 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy	Phase 2/3	Recruiting	Tongji Hospital	China
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) NCT06796803 · ClinicalTrials.gov ↗ · Potentially Resectable Hepatocellular Carcinoma	Phase 2/3	Recruiting	Shanghai Zhongshan Hospital	China
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma NCT04299581 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Fudan University	China
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma NCT04331093 · ClinicalTrials.gov ↗ · Acral Melanoma	Phase 2	Recruiting	Di Wu	China
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients NCT05069857 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia NCT05139095 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) NCT05447702 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 2	Recruiting	West China Hospital	China
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma NCT05512481 · ClinicalTrials.gov ↗ · Melanoma, Acral Melanoma, Temozolomide	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389 · ClinicalTrials.gov ↗ · Germline BRCA-mutated HER2-negative Breast Cancer	Phase 2	Recruiting	Peking University People's Hospital	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. NCT05624099 · ClinicalTrials.gov ↗ · Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms	Phase 2	Recruiting	Fujian Cancer Hospital	China
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434 · ClinicalTrials.gov ↗ · Esophageal Cancer by AJCC V8 Stage	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
FUSCC Refractory TNBC Platform Study (FUTURE2.0) NCT05749588 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470 · ClinicalTrials.gov ↗ · Her-2 Negative Breast Cancer, HRR Gene Mutation	Phase 2	Recruiting	Ying Lin	China
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients NCT05825443 · ClinicalTrials.gov ↗ · Immunotherapy, Chemotherapy	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma NCT06163729 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06176885 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	yue junhan	China
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC NCT06241807 · ClinicalTrials.gov ↗ · IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma	Phase 2	Recruiting	Shandong Cancer Hospital and Institute	China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC NCT06288360 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative	Phase 2	Recruiting	Tongji Hospital	China
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer NCT06289062 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation	Phase 2	Recruiting	Tongji Hospital	China
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC NCT06360042 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma NCT06363825 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Fujian Medical University	China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs NCT06423170 · ClinicalTrials.gov ↗ · Unresectable Gallbladder Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer NCT06435260 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab NCT06516289 · ClinicalTrials.gov ↗ · BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer NCT06561308 · ClinicalTrials.gov ↗ · Endometrioid Endometrial Cancer	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer NCT06711471 · ClinicalTrials.gov ↗ · Gastric Cancer Adenocarcinoma Metastatic	Phase 2	Recruiting	LIN YANG	China
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma NCT06831175 · ClinicalTrials.gov ↗ · Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer	Phase 2	Recruiting	West China Hospital	China
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer NCT06869226 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer NCT07026149 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab NCT07100392 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) NCT07105748 · ClinicalTrials.gov ↗ · Mixed Hepatocellular-cholangiocarcinoma	Phase 2	Recruiting	Fudan University	China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial NCT07167160 · ClinicalTrials.gov ↗ · Cervical Cancer, Immunochemotherapy	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment NCT07238881 · ClinicalTrials.gov ↗ · Hepatocellulcar Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer NCT07320586 · ClinicalTrials.gov ↗ · Gastric Cancer, Second-line Therapy	Phase 2	Recruiting	Shandong Tumor Hospital	China
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC NCT07334483 · ClinicalTrials.gov ↗ · HCC	Phase 2	Recruiting	GrandPharma (China) Co., Ltd	China
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma NCT07505186 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer NCT07527026 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	Chinese PLA General Hospital	China
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma NCT07530094 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Ning Jiang, M.D./Ph.D	China
Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT07622797 · ClinicalTrials.gov ↗ · Late-stage Resectable Esophageal Squamous Carcinoma	Phase 2	Recruiting	The First Affiliated Hospital of Henan University of Science and Technology	China
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma NCT07787273 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab	Phase 2	Recruiting	Hefei Cancer Hospital of the Chinese Academy of Sciences	China
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment NCT07896096 · ClinicalTrials.gov ↗ · Refractory Metastatic Colorectal Cancer	Phase 2	Recruiting	Renmin Hospital of Wuhan University	China
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors NCT05699811 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer NCT05981001 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1/2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma	Phase 1/2	Recruiting	Beijing Tongren Hospital	China
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer NCT06121557 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma NCT05713994 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Observational	Recruiting	Ze-yang Ding, MD	China
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma NCT06323382 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab	Observational	Recruiting	Sun Yat-sen University	China
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma NCT06333561 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor	Observational	Recruiting	Sun Yat-sen University	China
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment NCT07147101 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Observational	Recruiting	Fudan University	China
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT NCT05772273 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Not applicable	Recruiting	The First Affiliated Hospital of Soochow University	China
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer NCT06326736 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Early Phase 1	Recruiting	Jinling Hospital, China	China
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion NCT07790419 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 4	Not yet open	Zhai Wenlong	China
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes NCT05610332 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer	Phase 3	Not yet open	Fujian Medical University	China
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients NCT06335355 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Shanghai Shengdi Pharmaceutical Co., Ltd	China
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes NCT05524974 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer	Phase 2	Not yet open	Fujian Medical University	China
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer NCT06423937 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Not yet open	Fudan University	China
First-line Treatment of Advanced/unresectable DDLPS NCT06694324 · ClinicalTrials.gov ↗ · Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)	Phase 2	Not yet open	Fudan University	China
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC NCT06731153 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer	Phase 2	Not yet open	Fudan University	China
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer NCT06745193 · ClinicalTrials.gov ↗ · Advanced Esophageal Carcinoma	Phase 2	Not yet open	Peking University	China
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer NCT06759090 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Carcinoma	Phase 2	Not yet open	Zhejiang University	China
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer NCT06849492 · ClinicalTrials.gov ↗ · Advanced Triple Negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer NCT07159217 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib	Phase 2	Not yet open	Peking Union Medical College Hospital	China
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma NCT07314372 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult	Phase 2	Not yet open	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer NCT07521605 · ClinicalTrials.gov ↗ · Rectal Cancer Patients	Phase 2	Not yet open	Guangdong Provincial People's Hospital	China
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma NCT07824856 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma NCT07902713 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sun Yat-sen University	China
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer NCT04616040 · ClinicalTrials.gov ↗ · Esophageal Cancer	Observational	Not yet open	Peking University	China
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer NCT07466901 · ClinicalTrials.gov ↗ · Cervical Cancer, Radical Surgery, Adjuvant Therapy	Not applicable	Not yet open	Jin LI	China
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma NCT07312578 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	By invitation	Peking University	China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation NCT04639180 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. NCT05043688 · ClinicalTrials.gov ↗ · Resectable Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Zhigang Li	China
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial NCT05198609 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma NCT05320692 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer NCT04208347 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2/3	Active, closed	Ruijin Hospital	China
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma NCT04521153 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy	Phase 2/3	Active, closed	Shanghai Zhongshan Hospital	China
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma NCT03950271 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	Henan Cancer Hospital	China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma NCT04067037 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma	Phase 2	Active, closed	Henan Cancer Hospital	China
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer NCT04379739 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Shanghai Pulmonary Hospital, Shanghai, China	China
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma NCT05524168 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study NCT05602935 · Stomach Neoplasms, Digestive System Neoplasms, Neoplasms	Phase 2	Active, closed	The Second Affiliated Hospital of Fujian Medical University	China
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer NCT06215677 · ClinicalTrials.gov ↗ · Colon Cancer, Mismatch Repair Deficiency, Immunotherapy	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer NCT06693128 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Active, closed	Ruijin Hospital	China
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy NCT07471815 · ClinicalTrials.gov ↗ · Breast Cancer Triple Negative Breast Cancer	Phase 2	Active, closed	Harbin Medical University	China
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer NCT07791602 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment NCT04706598 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Immunotherapy	Phase 1/2	Active, closed	Fudan University	China
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. NCT05176002 · ClinicalTrials.gov ↗ · Esophageal Neoplasm, Immunotherapy, Radiotherapy	Phase 1/2	Active, closed	Fujian Medical University Union Hospital	China
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas NCT06654297 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1	Active, closed	West China Hospital	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Camrelizumab

136 conditions

Nasopharyngeal Carcinoma7 Immunotherapy6 Hepatocellular Carcinoma5 Cervical Cancer5 Hepatocellular Carcinoma (HCC)3 Gastric Cancer3Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma3Acral Melanoma3Esophageal Squamous Cell Carcinoma3 Neoadjuvant Therapy3 Neoadjuvant Chemoimmunotherapy3 Pancreatic Cancer3

All 136 conditions

Condition (as registered)	Trials
Nasopharyngeal Carcinoma	7
Immunotherapy	6
Hepatocellular Carcinoma	5
Cervical Cancer	5
Hepatocellular Carcinoma (HCC)	3
Gastric Cancer	3
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	3
Acral Melanoma	3
Esophageal Squamous Cell Carcinoma	3
Neoadjuvant Therapy	3
Neoadjuvant Chemoimmunotherapy	3
Pancreatic Cancer	3
Advanced Hepatocellular Carcinoma	2
Lenvatinib	2
Locally Advanced Cervical Cancer	2
Esophageal Cancer	2
Esophageal Neoplasms	2
Digestive System Neoplasms	2
Locally Advanced Gastric Cancer	2
Breast Cancer	2
Chemotherapy	2
Breast Neoplasms	2
Radiotherapy	2
Colorectal Cancer	2
Unresectable Hepatocellular Carcinoma (HCC)	1
Liver Cancer Adult	1
Salivary Gland Carcinoma	1
Precision Therapy	1
TNBC - Triple-Negative Breast Cancer	1
Late-stage Resectable Esophageal Squamous Carcinoma	1
Unresectable Hepatocellular Carcinoma	1
Adrenal Cortical Carcinoma	1
Adrenal Cortical Cancer	1
Adrenal Cancer	1
Molecular Targeted Therapy	1
Biliary Tract Cancer	1
Disitamab Vedotin	1
Immune Checkpoint Inhibitors	1
Breast Cancer Triple Negative Breast Cancer	1
Concurrent Chemoradiotherapy	1
Refractory Metastatic Colorectal Cancer	1
Gestational Trophoblastic Neoplasia	1
Second-line Therapy	1
Preoperative	1
Squamous Non-Small Cell Lung Cancer sqNSCLC	1
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	1
Esophageal Diseases	1
Dedifferentiated Liposarcoma	1
Soft Tissue Sarcoma (STS)	1
HCC - Hepatocellular Carcinoma	1
Locally Advanced Esophageal Squamous Cell Carcinoma	1
Camrelizumab	1
Hepatocellular Carcinoma Non-resectable	1
Resectable Esophageal Squamous Cell Carcinoma	1
Triple Negative Breast Cancer	1
Oral Squamous Cell Carcinoma	1
Neoadjvant Therapy	1
Anti-PD-1	1
Anti-VEGFR	1
Urinary Bladder Neoplasms	1
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	1
T-lymphoblastic Lymphoma	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	1
Breast Cancer Stage IV	1
Triple -Negative Breast Cancer	1
PD-L1 Negative	1
Nasopharyngeal Cancer	1
PD-1 Therapy	1
BRCA-Mutated Breast Carcinoma	1
HER2-negative Breast Cancer	1
Esophageal Neoplasm	1
Germline BRCA-mutated HER2-negative Breast Cancer	1
HCC	1
PD-1 Inhibitor	1
Hepatic Arterial Infusion Chemotherapy	1
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	1
Anti-PD1/PDL1 Antibody	1
Bevacizumab	1
Esophageal Cancer by AJCC V8 Stage	1
Fertility Preservation	1
Locally Advanced or Metastatic Solid Tumors	1
Triple-Negative Breast Cancer	1
Stomach Neoplasms	1
Neoplasms	1
Digestive System Diseases	1
Metastatic Pancreatic Carcinoma	1
PDAC - Pancreatic Ductal Adenocarcinoma	1
Pancreas Cancer	1
Pancreatic Neoplasms	1
Liver Cancer	1
Hepato Cellular Carcinoma (HCC)	1
Nasopharyngeal Carcinoma (NPC)	1
Locally Advanced Rectal Cancer	1
Endometrioid Endometrial Cancer	1
Hepatocellulcar Carcinoma	1
Intrahepatic Cholangiocarcinoma	1
Non Small Cell Lung Cancer	1
Rectal Cancer Patients	1
Endometrial Carcinoma	1
TP53 Mutation	1
Recurrent or Metastatic	1
Triple Negative Breast Cancer (TNBC)	1
Metastatic Breast Cancer	1
Mixed Hepatocellular-cholangiocarcinoma	1
Potentially Resectable Hepatocellular Carcinoma	1
Her-2 Negative Breast Cancer	1
HRR Gene Mutation	1
Head and Neck Squamous Cell Carcinoma	1
Locally Advanced Head and Neck Cancer	1
HNSCC	1
Gastric Cancer Adenocarcinoma Metastatic	1
Classical Hodgkin Lymphoma	1
Immunochemotherapy	1
Colon Cancer	1
Mismatch Repair Deficiency	1
Radical Surgery	1
Adjuvant Therapy	1
Unresectable Gallbladder Cancer	1
Non-squamous Non-small Cell Lung Cancer	1
Acute Myeloid Leukemia	1
Advanced Hepatocellular Carcinoma (HCC)	1
Advanced Esophageal Carcinoma	1
Melanoma	1
Temozolomide	1
Apatinib	1
Neoplasm Metastasis	1
Lung Metastases	1
Liver Metastases	1
IMMUNOTHERAPY	1
Resectable Lung Non-Small Cell Carcinoma	1
Biomarkers / Blood	1
Advanced Triple Negative Breast Cancer	1
Triple-negative Breast Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	108	72

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Camrelizumab trials

How many clinical trials are testing Camrelizumab?

108 current trials in our China register name Camrelizumab (also registered as SHR-1210) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.

Are Camrelizumab trials recruiting patients?

Yes. 72 of the 108 trials are recruiting: 72 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Camrelizumab clinical trials?

Fudan University (16), Sun Yat-sen University (11), Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5) and Peking University Cancer Hospital & Institute (4), among 53 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Camrelizumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Camrelizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Camrelizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.